Abstract
The fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) has identified a new classification system for tumors of the brain and spinal cord, highlighting the pivotal role of molecular diagnosis in accurately categorizing neoplasms. In addition to previous classifications, one of the key distinctions lies in categorizing pediatric-type diffuse low-grade gliomas (pDLGGs) and pediatric-type diffuse high-grade gliomas (pDHGGs) as distinct tumor types. Although similar in histology and morphology, pediatric diffuse gliomas are completely different from the adult type with respect to the molecular genetic characteristics, prognosis, and treatment strategies. pDLGG includes four tumor types, namely, diffuse astrocytoma, MYB- or MYBL1-altered; angiocentric glioma; polymorphous low-grade neuroepithelial tumor of the young (PLNTY); and diffuse low-grade glioma, MAPK pathway-altered, three types of which are newly recognized tumor types. This review aims to evaluate and update the relevant pDLGG features and advances in neuroimaging that may assist in differential diagnosis, surgery planning, and prognostic determination.
Introduction: The Shift from Histology to Molecular Genetics
Historically, pediatric and adult gliomas were grouped together because they appear similar under a microscope. However, pediatric gliomas behave very differently: they possess distinct genetic drivers, generally offer better prognoses, and require specialized treatment strategies. The 2021 WHO CNS5 update officially split diffuse gliomas into "adult-type" and "pediatric-type," reflecting a shift where a tumor’s genetic makeup (e.g., MYB-QKI fusion or BRAF V600E mutation) is now more critical for classification than its cellular morphology.
Characterizing pDLGG Subtypes
This review synthesizes current literature to characterize the four recognized pDLGG subtypes across molecular, clinical, and radiological dimensions. A common clinical thread among these tumors is their "epileptogenic" nature; they are frequently discovered during workups for intractable childhood seizures, particularly when located in the temporal lobe.
1. Diffuse Astrocytoma, MYB- or MYBL1-Altered
Generally classified as WHO Grade 1, these tumors have an excellent prognosis, with a 10-year survival rate of approximately 95.2%. Neuroimaging typically reveals well-circumscribed lesions with T2 hyperintensity and a notable lack of contrast enhancement.
2. Angiocentric Glioma (AG)
Defined by the MYB-QKI gene fusion, AG is a stable, slow-growing tumor. A hallmark neuroimaging feature is the "stalk-like sign," where the tumor appears to follow vessels extending from the brain surface toward the ventricles. Surgical resection often leads to significant improvement in seizure control.
3. Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY)
PLNTY is a newly recognized entity often found in the temporal lobe (80% of cases). It is characterized by intense CD34 expression and frequent calcification. On MRI, it often presents with a "salt and pepper sign," where granular calcifications create a distinct speckled appearance on T2-weighted sequences.
4. Diffuse Low-Grade Glioma, MAPK Pathway-Altered
This category involves mutations in FGFR1 or BRAF. It is currently considered an "intermediate risk" group. Unlike the other subtypes, it has not yet been assigned a formal WHO grade due to limited long-term data, though it frequently presents with calcifications on CT imaging.
Conclusion and Future Directions
While molecular testing remains the gold standard for diagnosis, specific neuroimaging "signatures" like the stalk-like sign in AG or the salt and pepper sign in PLNTY provide critical early clues for clinicians. As advanced imaging techniques like MR spectroscopy and perfusion-weighted imaging become more integrated with molecular diagnostics, the goal is to move toward "virtual biopsies" that can non-invasively guide surgical planning and targeted therapy for pediatric patients.
Summary updated